| SATELLITE SYMPOSIUM
1 |
 |
Improving Bone Strength, Reducing Fractures:
Targeting Osteoporosis
Treatment
SUPPORTED BY ROCHE/GSK
Chair: Rick Adachi (Hamilton, Canada)
|
|
IBANDRONATE: A REVIEW OF THE WEALTH OF EVIDENCE
Socrates Papapoulos (Leiden, Netherlands) |
|
BONE STRENGTH: A KEY TARGET IN BISPHOSPHONATE
EFFICACY
Dieter Felsenberg (Berlin, Germany) |
|
IBANDRONATE IN FOCUS: NON-VERTEBRAL ANTIFRACTURE
EFFICACY
Rick Adachi (Hamilton, Canada) |
|
COMPARING BISPHOSPHONATE EFFICACY
Steven Harris (San Francisco, USA)
|
|
| SATELLITE SYMPOSIUM 2 |
|
Expanding the Spectrum of Osteoporosis
Treatment: Patient-Centered Approaches
SUPPORTED BY NOVARTIS
Chairs: Adolfo Diez-Perez (Barcelona, Spain) |
|
Socrates Papapoulos (Leiden, Netherlands)
THE POSTMENOPAUSAL OSTEOPOROSIS PATIENT: NEW INSIGHTS IN TREATMENT
WITH ZOLEDRONIC ACID
René Rizzoli (Geneva, Switzerland) |
|
THE POSTMENOPAUSAL OSTEOPOROSIS PATIENT: SUBGROUP
ANALYSES FROM THE HORIZON-PFT TRIAL
Richard Eastell (Sheffield, UK) |
|
THE POST-HIP FRACTURE PATIENT: THE PREVENTION OF NEW
FRACTURES AFTER A HIP FRACTURE WITH ZOLEDRONIC ACID
Lars Nordsletten (Oslo, Norway) |
|
THE GLUCOCORTICOID-INDUCED OSTEOPOROSIS PATIENT: NEW
STRATEGIES TO IMPROVE OUTCOMES
David Reid (Aberdeen, UK)
|
|
| SATELLITE SYMPOSIUM 3 |
|
Role of Teriparatide Treatment in Primary
and Secondary Osteoporosis
SUPPORTED BY ELI LILLY
Chair: Graham Russell (Oxford, UK) |
|
THE USE OF FINITE ELEMENT ANALYSIS TO EVALUATE BONE
MECHANICAL PROPERTIES: RESULTS FROM THE EUROFORS CLINICAL TRIAL
Philippe Zysset (Vienna, Austria) |
|
TERIPARATIDE TREATMENT IN PATIENTS WITH GLUCOCORTICOID-INDUCED
OSTEPOROSIS
Juliet Compston (Cambridge, UK) |
|
PTH 1-34 AND 1-84
Silvano Adami (Verona, Italy)
|
|
| SATELLITE SYMPOSIUM 4 |
|
New Insights on the Role of RANK/ RANKL/OPG
Pathway in Bone Loss
SUPPORTED BY AMGEN
Chair: Adolfo Diez Perez (Barcelona, Spain) |
|
CORTICAL BONE - FROM ARCHITECTURE TO NON-VERTEBRAL
FRACTURE
Socrates Papapoulos (Leiden, Netherlands) |
|
RANK LIGAND INHIBITION INCREASES BONE STRENGTH: FROM
RATS TO PRIMATES
Paul Kostenuik (Thousand Oaks, USA) |
|
TARGETING RANK LIGAND INCREASES BONE MINERAL DENSITY
IN POST-MENOPAUSAL WOMEN
René Rizzoli (Geneva, Switzerland)
|
|
| SATELLITE SYMPOSIUM 5 |
|
Emerging Data for Osteoporosis Management
with Bisphosphonate Therapy
SUPPORTED BY THE ALLIANCE FOR BETTER BONE HEALTH
(P&G PHARMACEUTICALS AND SANOFI-AVENTIS)
Chair: Steven Boonen (Leuven, Belgium)
|
|
OPTIMISING PATIENT OSTEOPOROSIS TREATMENT: IMPORTANCE
OF CALCIUM AND VITAMIN D
Steven Boonen (Leuven, Belgium) |
|
IMPORTANCE OF EARLY FRACTURE PROTECTION: EXPLORING
BEYOND POSTMENOPAUSAL OSTEOPOROSIS
Christian Roux (Paris, France) |
|
NEW PERSPECTIVES FROM OSTEOPOROSIS OBSERVATIONAL STUDIES:
THE GLOW AND REAL STUDIES
Pierre D. Delmas (Lyon, France) |
|
CONNECTING CLINICAL INSIGHTS AND EVIDENCE FOR VARIATIONS
IN MECHANISTIC PHARMACOLOGY OF BISPHOSPHONATES
Robert Lindsay (New York, USA)
|
|
| SATELLITE SYMPOSIUM 6 |
|
Foundation, Flexibility and Freedom - Optimising
Osteoporosis Treatment
SUPPORTED BY NYCOMED
Chair: Cyrus Cooper (Southampton, UK) |
|
WHAT HAVE RECENT META-ANALYSES TAUGHT US ABOUT CALCIUM
AND VITAMIN D SUPPLEMENTATION IN THEMANAGEMENT OF OSTEOPOROSIS?
Lars Hyldstrup (Copenhagen, Denmark) |
|
PTH (1-84) BUILDS NEW BONE OF GOOD QUALITY
David Hanley (Calgary, Canada) |
|
UNDERSTANDING PTH AND CALCIUM BALANCE: RECENT DATA
FROM CLINICAL TRIALS
Santiago Palacios (Madrid, Spain) |
|
EMERGING STRATEGIES IN THE TREATMENT OF OSTEOPOROSIS
WITH PTH (1-84)
Dennis Black (San Francisco, USA)
|
|
| SATELLITE SYMPOSIUM 7 |
|
Advanced Mechanisms for the Management
of Metabolic Bone Disease
SUPPORTED BY MSD
Chair: Socrates Papapoulos (Leiden, Netherlands) |
|
THE EFFECT OF CHOLECALCIFEROL ON SWAY AND FALLS: NEW
CLINICAL DATA
Paul Lips (Amsterdam, Netherlands) |
|
NEW THERAPEUTIC OPTIONS TO TARGET BONE REMODELING
Roland Baron (Boston, USA) |
|
ODANACATIB: PHASE 2B RESULTS
Michael McClung (Portland, USA) |
|
